-- Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) reported earnings of $1.70 per share in the fourth-quarter 2019, vs. $1.20 per share expected. -- Total revenue
Vertex Pharmaceuticals Inc (VRTX): Q4 2019 Earnings Snapshot
Categories
Health Care
Amgen’s (AMGN) Q4 results beat estimates
Amgen Inc. (NASDAQ: AMGN) topped revenue and earnings estimates for the fourth quarter of 2019. However, shares fell 2.7% in aftermarket hours
Biogen (NASDAQ: BIIB): Q4 2019 Earnings Snapshot
-- Biogen Inc. (NASDAQ: BIIB) reported its fourth-quarter 2019 adjusted earnings of $8.34 per share versus $8.02 per share expected. -- Total
Eli Lilly (NYSE: LLY): Q4 2019 Earnings Snapshot
-- Eli Lilly and Company (NYSE: LLY) reported its fourth-quarter 2019 adjusted earnings of $1.73 per share versus $1.52 per share expected.
Alexion Pharmaceuticals, Inc. (ALXN): Earnings Snapshot
-- Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) reported earnings of $2.71 per share in the fourth-quarter 2019, vs. $2.60 per share expected. --
Anthem Inc (ANTM): Q4 2019 Earnings Snapshot
-- Anthem, Inc. (NYSE: ANTM) reported earnings of $3.88 per share in the fourth-quarter 2019, in line with the Street estimate. --
Stryker (SYK): Q4 2019 Earnings Snapshot
-- Stryker (NYSE: SYK) reported fourth quarter 2019 earnings of $2.49 per share, vs. $2.46 per share expected. -- Total sales grew
Pfizer beats Q4 revenue estimates; earnings miss expectations
Pfizer Inc. (NYSE: PFE) topped revenue expectations for the fourth quarter of 2019 while earnings missed the mark. Shares fell 1.6% in
Key factors to note when Pfizer (PFE) reports Q4 earnings results
Pfizer Inc. (NYSE: PFE) is scheduled to report fourth quarter 2019 earnings results on Tuesday, January 28, before the market opens. Both
Abbott Laboratories (ABT) reports in-line earnings for Q4; guides FY20
Abbott Laboratories (NYSE: ABT) reported a marked increase in fourth-quarter earnings as the drugmaker's strong product portfolio boosted sales in the key
Johnson & Johnson (JNJ) beats Q4 earnings estimates, misses on revenue
Johnson & Johnson (NYSE: JNJ) topped earnings estimates for the fourth quarter of 2019 while revenues fell short of expectations. The shares
PetMed Express (NASDAQ: PETS) Q3 2019 Earnings Call Transcript
PetMed Express Inc (PETS) Q3 2019 Earnings Conference Call Final Transcript Corporate Participants Bruce S. Rosenbloom Chief Financial Officer and Treasurer | PetMed
PetMed (PETS) Q3 earnings drop but beat Street view; sales miss
Earnings of PetMed Express Inc. (NASDAQ: PETS) decreased in the third quarter even as net sales remained unchanged. The bottom line, however,
PetMed Express (PETS) likely to report weak Q3 earnings on Jan 21
PetMed Express Inc. (NASDAQ: PETS) is slated to report its third-quarter 2020 earnings results on Tuesday, January 21, before the market opens.
UnitedHealth Group beats Q4 earnings estimates; revenues match expectations
UnitedHealth Group (NYSE: UNH) reported better-than-expected earnings for the fourth quarter of 2019 while revenues matched estimates. Shares were down 0.40% in
Boston Scientific (BSX) stock drops on weak Q4 preliminary revenue
Boston Scientific Corporation (NYSE: BSX) stock dropped over 6% on Tuesday after its preliminary fourth-quarter report. The shares have fallen over 5%
UnitedHealth (UNH) Q4 earnings preview: Get ready for another good show
UnitedHealth Group (NYSE: UNH) has been expanding its market value steadily, especially after reporting stronger-than-expected third-quarter results a few months ago. Since
Walgreens (WBA) Q1 profit drops 25%, misses estimates
Walgreens Boots Alliance Inc. (NASDAQ: WBA) reported a 25% drop in earnings for the first quarter of 2020 due to higher charges
New hope for investors as Amarin (AMRN) sees a promising year ahead
Though Amarin Corporation (NASDAQ: AMRN) has been showing signs of recovery since last year, after staying low for several years, the stock
SmileDirectClub (SDC) stock rebounds amid growth prospects concern
SmileDirectClub Inc. (NASDAQ: SDC) stock rebounded over 26% in the past month on bullish outlook after the launch of a suite of
AngioDynamics (ANGO): Q2 2020 Earnings Snapshot
-- AngioDynamics Inc. (NASDAQ: ANGO) reported Q2 2020 earnings of $0.06 per share, vs. $0.02 expected. -- Net sales remained flat at